Pleomorphic Xanthoastrocytoma: a single institution retrospective analysis and a review of the literature.
Brain tumor
Pleomorphic Xanthoastrocytoma
Radiotherapy
Journal
La Radiologia medica
ISSN: 1826-6983
Titre abrégé: Radiol Med
Pays: Italy
ID NLM: 0177625
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
07
07
2021
accepted:
22
07
2022
pubmed:
12
8
2022
medline:
28
9
2022
entrez:
11
8
2022
Statut:
ppublish
Résumé
Pleomorphic xanthoastrocytoma (PXA) is a rare low-grade brain tumor. To date, limited studies have analyzed factors affecting survival outcomes and defined the therapeutic strategy. The aim of this retrospective analysis was to investigate the clinicopathologic characteristics of PXA and identify factors associated with outcomes. We retrospectively analyzed a cohort of 16 adult and children patients with PXA who underwent primary resection from 1997 to 2019, referred to our Radiation Oncology Unit and to Meyer's Paediatric Hospital. We also reviewed the relevant literature. All patients underwent primary surgical resection; 10 patients received adjuvant radiation treatment course, ranging from DTF 54 to 64 Gy; 8 of them received, in addition, concurrent adjuvant chemotherapy; 6 patients underwent only radiological follow-up. After a median follow up was 60 months: median OS was 34.9 months (95% CI 30-218), 1-year OS 87%, 5-years OS 50%, 10-years OS 50%; median PFS 24.4 months (95% CI 13-156), 1-year PFS 80%, 5-years PFS 33%, 10-years PFS 33%. A chi-square test showed a significant association between OS and recurrent disease (p = 0.002) and with chemotherapy adjuvant treatment (p = 0.049). A borderline statistical significant association was instead recognized with BRAF mutation (p = 0.058). Despite our analysis did not reveal a strong prognostic or predictive factor able to address pleomorphic xanthoastrocytoma management; however, in selected patients could be considered the addition of adjuvant radiation chemotherapy treatment after adequate neurosurgical primary resection. Furthermore, recurrent disease evidenced a detrimental impact on survival.
Sections du résumé
BACKGROUND
BACKGROUND
Pleomorphic xanthoastrocytoma (PXA) is a rare low-grade brain tumor. To date, limited studies have analyzed factors affecting survival outcomes and defined the therapeutic strategy. The aim of this retrospective analysis was to investigate the clinicopathologic characteristics of PXA and identify factors associated with outcomes.
METHODS
METHODS
We retrospectively analyzed a cohort of 16 adult and children patients with PXA who underwent primary resection from 1997 to 2019, referred to our Radiation Oncology Unit and to Meyer's Paediatric Hospital. We also reviewed the relevant literature.
RESULTS
RESULTS
All patients underwent primary surgical resection; 10 patients received adjuvant radiation treatment course, ranging from DTF 54 to 64 Gy; 8 of them received, in addition, concurrent adjuvant chemotherapy; 6 patients underwent only radiological follow-up. After a median follow up was 60 months: median OS was 34.9 months (95% CI 30-218), 1-year OS 87%, 5-years OS 50%, 10-years OS 50%; median PFS 24.4 months (95% CI 13-156), 1-year PFS 80%, 5-years PFS 33%, 10-years PFS 33%. A chi-square test showed a significant association between OS and recurrent disease (p = 0.002) and with chemotherapy adjuvant treatment (p = 0.049). A borderline statistical significant association was instead recognized with BRAF mutation (p = 0.058).
CONCLUSIONS
CONCLUSIONS
Despite our analysis did not reveal a strong prognostic or predictive factor able to address pleomorphic xanthoastrocytoma management; however, in selected patients could be considered the addition of adjuvant radiation chemotherapy treatment after adequate neurosurgical primary resection. Furthermore, recurrent disease evidenced a detrimental impact on survival.
Identifiants
pubmed: 35951279
doi: 10.1007/s11547-022-01531-3
pii: 10.1007/s11547-022-01531-3
pmc: PMC9512734
doi:
Substances chimiques
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1134-1141Informations de copyright
© 2022. The Author(s).
Références
Cancer. 1999 May 1;85(9):2033-45
pubmed: 10223246
Brain Pathol. 2014 Apr;24(3):221-9
pubmed: 24345274
Epidemiol Prev. 2016 Jan-Feb;40(1 Suppl 2):1-120
pubmed: 26951748
J Neurooncol. 2013 Sep;114(2):237-40
pubmed: 23756728
Acta Neuropathol. 2011 Mar;121(3):397-405
pubmed: 21274720
Childs Nerv Syst. 2019 Feb;35(2):355-362
pubmed: 30182181
Cancer. 1979 Nov;44(5):1839-52
pubmed: 498051
CNS Oncol. 2018 Apr;7(2):CNS10
pubmed: 29708404
J Pediatr Hematol Oncol. 2020 Mar;42(2):152-155
pubmed: 30601402
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Cureus. 2018 May 21;10(5):e2665
pubmed: 30042916
Pediatr Blood Cancer. 2010 Aug;55(2):290-4
pubmed: 20582976
Int J Clin Exp Pathol. 2019 Apr 01;12(4):1118-1123
pubmed: 31933927
J Clin Oncol. 2017 Jul 20;35(21):2439-2449
pubmed: 28640707
J Neurosurg Pediatr. 2019 Feb 8;:1-5
pubmed: 30738389
Br J Neurosurg. 2013 Dec;27(6):759-64
pubmed: 23514331
CNS Oncol. 2019 Nov 1;8(3):CNS39
pubmed: 31535562
Front Oncol. 2019 Apr 12;9:277
pubmed: 31032231
Sci Rep. 2018 Sep 24;8(1):14275
pubmed: 30250216
Neuropathology. 2010 Aug;30(4):443-8
pubmed: 20051018
Childs Nerv Syst. 2004 Feb;20(2):119-22
pubmed: 14669022
Int J Hematol Oncol Stem Cell Res. 2018 Oct 1;12(4):265-272
pubmed: 30774826
Brain Pathol. 2019 Jan;29(1):85-96
pubmed: 30051528
World Neurosurg. 2019 Jun;126:624-630
pubmed: 30599247
J Neuropathol Exp Neurol. 2015 Oct;74(10):960-9
pubmed: 26352988
J Clin Oncol. 2018 Dec 10;36(35):3477-3484
pubmed: 30351999
Medicine (Baltimore). 2020 Jan;99(3):e18880
pubmed: 32011515
J Neurol. 2020 Mar;267(3):783-790
pubmed: 31748891
J Neurooncol. 2012 Oct;110(1):99-104
pubmed: 22843450
Brain Pathol. 2015 Sep;25(5):575-86
pubmed: 25318587
J Neurosci Rural Pract. 2019 Jul;10(3):430-437
pubmed: 31595115
PLoS One. 2016 Jun 02;11(6):e0156422
pubmed: 27253461
J Clin Neurosci. 2018 Aug;54:57-62
pubmed: 29803334
World Neurosurg. 2018 Dec;120:e1225-e1233
pubmed: 30240866